National Pension Service Sells 63,795 Shares of DexCom, Inc. $DXCM

Key Points

• The National Pension Service reduced its holdings in DexCom, Inc. by 10.3%, selling 63,795 shares and retaining approximately 552,935 shares valued at $37.76 million.
• Analysts have recently set new price targets for DexCom, with Mizuho raising its target to $100 and Goldman Sachs initiating coverage with a target of $104.
• The company's latest quarterly earnings exceeded expectations, posting $0.48 EPS and $1.16 billion in revenue, reflecting a 15.2% increase from the previous year.

National Pension Service lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 10.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 552,935 shares of the medical device company's stock after selling 63,795 shares during the quarter. National Pension Service owned approximately 0.14% of DexCom worth $37,760,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the last quarter. Private Trust Co. NA grew its stake in shares of DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of DexCom by 29.3% in the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares during the last quarter. Dynamic Advisor Solutions LLC grew its stake in shares of DexCom by 34.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC grew its stake in shares of DexCom by 944.5% in the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock worth $220,000 after purchasing an additional 2,909 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DexCom stock traded down $0.1250 on Thursday, reaching $81.5450. 492,799 shares of the company traded hands, compared to its average volume of 3,860,105. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The company has a 50 day moving average of $82.85 and a 200 day moving average of $79.97. The firm has a market capitalization of $31.98 billion, a PE ratio of 56.67, a PEG ratio of 1.70 and a beta of 1.43. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm earned $0.43 EPS. The company's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This represents a 9.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director directly owned 33,411 shares of the company's stock, valued at $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,906 shares of company stock valued at $2,675,251 over the last quarter. 0.32% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Truist Financial started coverage on shares of DexCom in a research note on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Canaccord Genuity Group restated a "buy" rating and issued a $106.00 target price on shares of DexCom in a report on Friday, August 1st. Mizuho upped their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Finally, William Blair raised shares of DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $99.90.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.